Compare GEL & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEL | OGN |
|---|---|---|
| Founded | 1996 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | GEL | OGN |
|---|---|---|
| Price | $15.03 | $13.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.50 | $11.40 |
| AVG Volume (30 Days) | 176.7K | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.19% | 0.60% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $2,912,770,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $12.12 | $0.45 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | ★ N/A | $24.65 |
| Revenue Growth | ★ 43.60 | N/A |
| 52 Week Low | $13.75 | $5.69 |
| 52 Week High | $18.64 | $13.60 |
| Indicator | GEL | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 62.05 |
| Support Level | $14.89 | $13.46 |
| Resistance Level | $16.31 | $13.60 |
| Average True Range (ATR) | 0.42 | 0.04 |
| MACD | 0.12 | -0.02 |
| Stochastic Oscillator | 79.31 | 62.50 |
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.